Chloroquine (CQ) and hydroxychloroquine (HCQ) inhibit autophagy and have shown promise as adjuvant anticancer agents, particularly for targeting therapy-resistant cancer stem cells (CSCs). However, their clinical utility is limited by systemic toxicity and poor tumor selectivity. Here, we report the design, synthesis, and photochemical evaluation of 7-(diethylamino)coumarin-4-ylmethyl (DEACM)-caged CQ and HCQ derivatives as visible-light-activated autophagy inhibitors. Selective caging of the aliphatic amine suppressed biological activity in the dark and enabled rapid release of the parent drugs upon illumination. The lead compound 1C displayed robust light-dependent cytotoxicity across multiple cancer cell lines and, upon photoactivation, recapitulated CQ's effects on LC3-II accumulation. In CSC-enriched tumorspheres, 1C completely abolished sphere formation only if illuminated. Ex vivo and in vivo studies confirmed that visible light penetrates tumor tissue sufficiently to activate 1C and locally release CQ within the tumor. These findings establish the first proof of concept for light-controlled autophagy inhibition and provide a blueprint for spatiotemporally confined anticancer therapies based on photopharmacological modulation of CSCs.
Alonso-Manresa et al. (Tue,) studied this question.